COVID-19 Vaccine Response in People Living With Sickle Cell Disease

About the study

The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.

Study point of contact

Nicole Mortier
202-292-6005
[email protected]

Locations

6 United States sites

Genotypes

HbSS, HbSC, HbSB0 thalassemia

Study type

Observational

Age

-

Gender

All

Interventions

Biological

Compensation

Unknown

participation requirements

Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other)
Has not received any COVID-19 vaccination prior to enrollment
Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care
Willing and able to sign consent

participation restrictions

Unwilling to have labs drawn or complete study requirements.
Previous therapy curative of SCD (including bone marrow transplant and gene therapy)
Previous receipt of anti-COVID-19 antibody therapy

Locations

  • Washington, District of Columbia, United States, Children's National Medical Center, 20010 [Not yet recruiting]
  • Baltimore, Maryland, United States, Johns Hopkins University, 21205 [Not yet recruiting]
  • Bronx, New York, United States, Montefiore Hospital, 10467 [Not yet recruiting]
  • Durham, North Carolina, United States, Duke University Medical Center, 27710 [Not yet recruiting]
  • Greenville, South Carolina, United States, Prisma Health - Upstate, 29601 [Recruiting]
  • Dallas, Texas, United States, University of Texas Southwestern Medical Center, 75390 [Not yet recruiting]
Last updated 2021-12-02